Cancer Institute And Hospital, Chinese Academy Of Medical Sciences
Clinical trials sponsored by Cancer Institute And Hospital, Chinese Academy Of Medical Sciences, explained in plain language.
-
Engineered virus targets Hard-to-Treat cancers in early trial
Disease control ENROLLING_BY_INVITATIONThis early-phase trial tests an experimental virus-based treatment called IDOV-Immune in people with advanced solid tumors that have stopped responding to standard treatments. The virus is designed to infect and destroy cancer cells while leaving healthy cells alone. The study fo…
Phase: EARLY_PHASE1 • Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New radiation schedule aims to cut side effects for thymic cancer patients
Disease control OngoingThis study tests a shorter, more intense radiation schedule (hypofractionation) given after complete surgical removal of thymic tumors. The goal is to see if it can prevent the cancer from coming back while causing fewer side effects than standard radiation. About 50 adults with …
Phase: NA • Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New hope for tough lung cancer: drug plus radiation combo shows promise in early trial
Disease control OngoingThis early study tests whether combining a drug called lurbinectedin with radiation therapy is safe for people with small cell lung cancer that has one new tumor after initial treatment. The drug works by damaging cancer cell DNA, similar to radiation. The goal is to see if this …
Phase: PHASE2 • Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Shorter radiation after breast surgery shows promise for cancer control
Disease control OngoingThis study tests whether a shorter, more focused radiation treatment (accelerated partial breast irradiation) after breast-conserving surgery can effectively control cancer in the breast and nearby lymph nodes for people with early-stage breast cancer. About 537 participants with…
Phase: NA • Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
New combo therapy aims to wipe out lymphoma without prior treatment
Disease control OngoingThis study tests a combination of three drugs (orelabrutinib, zuberitamab, and chemotherapy) in 65 adults with untreated marginal zone lymphoma, a slow-growing blood cancer. The goal is to see if the treatment can make all signs of cancer disappear for at least 24 months. Partici…
Phase: PHASE2 • Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
New immunotherapy combo shows promise for stubborn lymphoma
Disease control OngoingThis phase 2 trial tests a combination of the immunotherapy drug glofitamab plus two chemotherapy drugs (gemcitabine and oxaliplatin) in 40 adults with refractory diffuse large B-cell lymphoma that did not respond to initial treatment. The main goal is to see how many patients ac…
Phase: PHASE2 • Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC
-
Immunotherapy plus chemo and radiation shows promise for bulky lung cancer
Disease control OngoingThis phase 2 trial tests whether adding the immunotherapy drug toripalimab to standard chemotherapy and radiation can help people with large, locally advanced non-small cell lung cancer. About 50 participants will receive two cycles of toripalimab plus chemo, followed by chemorad…
Phase: PHASE2 • Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
Could extra radiation after mastectomy keep breast cancer from coming back?
Disease control OngoingThis study looks at whether giving extra radiation to lymph nodes behind the breastbone can help prevent breast cancer from returning in high-risk patients. About 2,400 people who had a mastectomy and had cancer in their lymph nodes will take part. The goal is to see if this extr…
Phase: PHASE3 • Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC
-
New combo therapy aims to boost survival in advanced cervical cancer
Disease control OngoingThis phase II trial is testing whether adding the immunotherapy drug toripalimab to standard chemoradiotherapy can improve outcomes for patients with high-risk locally advanced cervical cancer. About 57 participants will receive the combination, followed by maintenance toripalima…
Phase: PHASE2 • Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences • Aim: Disease control
Last updated Jun 27, 2026 08:08 UTC
-
New hope for rare cancer: drug cocktail targets stubborn LCH
Disease control OngoingThis phase 2 trial tests a combination of three drugs—selinexor, thalidomide, and dexamethasone—in 40 adults with relapsed or refractory Langerhans cell histiocytosis (LCH), a rare immune cell disorder. The goal is to see if the XTD regimen can shrink tumors and delay disease pro…
Phase: PHASE2 • Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences • Aim: Disease control
Last updated Jun 27, 2026 07:52 UTC
-
AI could replace biopsies for bladder cancer testing
Diagnosis ENROLLING_BY_INVITATIONThis study enrolls 4,000 people with urothelial carcinoma to test whether artificial intelligence can predict HER2 expression using MRI scans and pathology images. The goal is to create a model that accurately assesses HER2 status without needing invasive biopsies, helping doctor…
Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences • Aim: Diagnosis
Last updated Jun 27, 2026 09:10 UTC
-
Can we predict who will benefit from immunotherapy? new study aims to find out.
Knowledge-focused OngoingThis study is looking for biological markers (biomarkers) that might predict how well patients with certain types of squamous cell carcinoma respond to a type of immunotherapy called PD-1 inhibitors. Researchers will analyze blood and tumor tissue samples from 800 patients, both …
Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:00 UTC
-
Saliva test could predict reflux after esophageal cancer surgery
Knowledge-focused ENROLLING_BY_INVITATIONThis observational study follows 138 people who had surgery for esophageal cancer. Researchers use a saliva test called PEPTEST to measure reflux before and after surgery. The goal is to understand how often reflux happens and what factors, like surgical technique or lifestyle, m…
Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:04 UTC
-
Blood test may forecast lymphoma prognosis
Knowledge-focused OngoingThis study looks at whether tracking tiny bits of tumor DNA in the blood (ctDNA) can help predict how B-cell non-Hodgkin lymphoma will progress. Researchers will collect blood samples from 60 patients before and during treatment. The goal is to see if changes in ctDNA levels matc…
Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:03 UTC
-
New study aims to improve survival in advanced stomach cancer
Knowledge-focused OngoingThis study looks back at 300 people with advanced stomach or gastroesophageal junction cancer to see how different treatments before and after surgery affect survival. The goal is to find out which treatment plans work best and whether tumor shrinkage after pre-surgery therapy pr…
Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:08 UTC
-
Massive study seeks to unlock best Post-Surgery care for lung cancer patients
Knowledge-focused OngoingThis study looks back at medical records of 10,000 people with non-small cell lung cancer who received immunotherapy before surgery. Researchers want to find out which follow-up treatments after surgery help patients live longer and reduce the chance of cancer coming back. The go…
Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:00 UTC